January 20, 2021

Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): treatment

A randomized trial (n=659) of patients hospitalized with mild to moderate COVID-19 who were taking angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) before hospital admission found no significant difference between the mean number of days alive and out of the hospital for those assigned to discontinue vs. continue these medications (21.9 vs. 22.9 days). There also was no statistically significant difference in death (OR=0.97), cardiovascular death (OR=1.95) or COVID-19 progression (OR=1.30). 

Lopes et al. (Jan 19, 2021). Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19. JAMA. https://doi.org/10.1001/jama.2020.25864